TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03814083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: No intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wait-list
Description: No intervention
Study: NCT00810355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: General support and problem solving for work activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group
Description: General support and problem solving for work activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group
Description: General support and problem solving for work activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Individual and group therapy focused on identifying and correcting maladaptive beliefs about work

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Individual and group therapy focused on identifying and correcting maladaptive beliefs about work

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computerized training to enhance cognitive functioning.
Study: NCT01479023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287
Study: NCT01684046

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS
Study: NCT01479023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)
Study: NCT01313676

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator once daily via novel dry powder inhaler
Study: NCT01684046

Intervention type: DEVICE
Group type: OTHER
Intervention: RevitaLens MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: RevitaLens MPDS

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
Study: NCT03312114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
Study: NCT01479023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)
Study: NCT01612858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
Study: NCT01684046

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
Study: NCT02838316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Description: Autologous muscle derived stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Description: Autologous muscle derived stem cells
Study: NCT01359137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probation as usual
Description: Routine probation with do deferred jail condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deferred Jail
Description: Discretionary deferred jail in response to violations of probation conditions.
Study: NCT00397215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
Study: NCT02949531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Study: NCT01706978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Trephination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Trephination
Study: NCT01669135

Intervention type: OTHER
Group type: OTHER
Intervention: Spinal Anesthesia with cerebral oxygen saturation monitoring
Study: NCT03515252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Killer Cells (IKC)
Study: NCT00607984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa melphalan
Description: thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
Study: NCT04330274

Intervention type: OTHER
Intervention: Bipedal with open eyes
Description: Standing bipedal with open eyes on force platform

Intervention type: OTHER
Intervention: Bipedal with open eyes
Description: Standing bipedal with open eyes on force platform

Intervention type: OTHER
Intervention: Bipedal with closed eyes
Description: Standing bipedal with closed eyes on force platform

Intervention type: OTHER
Intervention: Bipedal with closed eyes
Description: Standing bipedal with closed eyes on force platform

Intervention type: OTHER
Intervention: Bipedal with open eyes and with platform
Description: Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform

Intervention type: OTHER
Intervention: Bipedal with open eyes and with platform
Description: Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform

Intervention type: OTHER
Intervention: Bipedal with closed eyes and with platform
Description: Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform

Intervention type: OTHER
Intervention: Bipedal with closed eyes and with platform
Description: Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
Study: NCT01359137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arizona's SAFE
Description: Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
Study: NCT04444180

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual hand illusion (VHI)
Description: Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual hand illusion (VHI)
Description: Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
Study: NCT04433663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis
Description: To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis
Description: To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome.
Study: NCT04444180

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual hand illusion (VHI)
Description: Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
Study: NCT01385280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic estradiol
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study: NCT04358861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical Root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical Root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental operating microscope
Description: Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
Study: NCT00668174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
Study: NCT04487587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cediranib, Olaparib
Description: Cediranib film coated tablet, Olaparib film coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib, Olaparib
Description: Cediranib film coated tablet, Olaparib film coated tablet
Study: NCT00287573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Express2
Description: Paclitaxel-Eluting Coronary Stent System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy (beta source)
Description: Brachytherapy (beta source)
Study: NCT03014102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin
Description: Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Thrombopoietin
Description: Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
Study: NCT02756104

Intervention type: OTHER
Group type: OTHER
Intervention: phenotyping Tcells
Description: Collecting blood for analyses of the T cells phenotypes

Intervention type: OTHER
Group type: OTHER
Intervention: phenotyping Tcells
Description: Collecting blood for analyses of the T cells phenotypes

Intervention type: OTHER
Group type: OTHER
Intervention: Supplementation in vitamin D
Description: Supplementation in vitamin D for the patients who are deficient on vitamin D
Study: NCT04416139

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion IV of Mesenchymal Stem cells
Description: Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
Study: NCT02735915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection
Study: NCT01796093

Intervention type: DRUG
Intervention: Digoxin and ivabradine
Description: No more details
Study: NCT04599114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIRTUES
Description: VIRTUES is a digital health platform that offers 2 way communication between clinicians and patients to address symptoms stemming from atrial fibrillation.
Study: NCT02028884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baseline Treatment
Description: As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline Treatment
Description: As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
Study: NCT03412526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
Study: NCT04228965

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
Study: NCT03412526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL administration
Description: TIL Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
Study: NCT04228965

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.